MariTide Amgen Monthly Weight Loss Injection: Real 2026 Data

The MariTide Amgen monthly weight loss injection is real—but it is still experimental and cannot be prescribed or bought as an approved medicine. In the 52-week Phase 2 trial, adults without diabetes lost 12.3% to 16.2% on average; 19.9% is the estimate if everyone stayed on treatment. Ten Phase 3 studies are publicly listed. MARITIME-1 and -2 have an estimated primary completion date of January 21, 2027, but Amgen has announced no results date, approval date, launch date, or price.

You probably got here because of one number: 20%. A shot you take once a month—not once a week—with weight loss that rivals anything on the market. That's the headline.

Here's what the headline skips: the 20% and the 12-to-16% both come from the same trial. They're both real. The difference between them is the single most useful thing you can understand about MariTide right now—and almost nobody explains it. We will, in plain English, about two scrolls down.

One more reason this page exists today: on August 4, 2026, Amgen said it would stop future development of another obesity drug, AMG 513, while the Phase 1 study keeps following people already enrolled. MariTide is now Amgen's lead late-stage obesity bet, backed by ten publicly listed Phase 3 studies when the Japan study is included. Amgen also said its higher second-quarter research spending was driven mainly by later-stage programs related to MariTide. This drug is not a rumor. It's just not for sale.

MariTide at a glance (August 2026)

This page is for you if: you saw a MariTide headline and want the real evidence · you want to know what “20% weight loss” actually means · you're curious whether monthly or even quarterly dosing is legit · you want to find a legitimate clinical trial.

This page is not the answer if: you need a medication you can start this month (start here instead) · you want a confirmed launch date or price (nobody has one) · you're looking for a website that sells “MariTide” as a medicine (no approved consumer product exists).

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Is the MariTide Amgen monthly weight loss injection available yet?

No. MariTide is an investigational medicine in Phase 3 clinical trials. It is not an FDA-approved product. No retail or mail-order pharmacy can dispense it to consumers as an approved medicine. There is no lawful pharmacy-compounded MariTide: FDA says biological products do not qualify for the compounding exemptions under sections 503A and 503B. The only publicly listed route that could provide MariTide in 2026 is a qualifying Amgen clinical trial, and some studies include placebo or blinded treatment.

Let's clear up the names first, because they confuse people. MariTide, maridebart cafraglutide, and AMG 133 are all the same drug: MariTide is the development name, maridebart cafraglutide is the scientific name, and AMG 133 was Amgen's earlier code. If you see any of the three, you're reading about the same molecule.

Why no doctor can write you a MariTide prescription

There is no FDA-approved MariTide label, set commercial dose, or pharmacy supply chain. There is also no lawful pharmacy-compounded version to prescribe because MariTide is a biologic. That's not a loophole a clever telehealth site can work around. Any page offering “MariTide prescriptions online” is offering a product that does not exist as an approved medicine. More on those claims below.

Why you won't find MariTide customer reviews on this page

There are no legitimate commercial MariTide customer reviews, and we won't invent them. The drug has never been sold as an approved medicine. Trial participants are research volunteers, and some studies use placebo or blinded treatment. A social post cannot prove which treatment, dose, or study assignment a person received. Trial anecdotes are not customer reviews, and they cannot tell you what routine use would feel like. When real, verifiable customer experiences exist someday, we'll report them. Until then, a customer-review section here would be fiction—and you'd be right to distrust any site that has one.

Want to see which official MariTide trials are still taking people? Jump to the August 2026 trial tracker below. We mapped the current Phase 3 program and the active Phase 2b liver-fat study, including the six public recruiting paths Amgen identified.

The right GLP-1 provider isn't the same for everyone—it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. A page about a drug you can't get yet can't resolve any of that for you. So if part of you is really asking “what should I do now,” use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

How much weight do people lose on MariTide?

In MariTide's 52-week Phase 2 trial, adults with obesity or overweight and no diabetes lost an average of 12.3% to 16.2% of their body weight, depending on dose, versus 2.5% on placebo. Adults with obesity or overweight and type 2 diabetes lost 8.4% to 12.3%, versus 1.7% on placebo. The higher figures you've seen—up to 19.9% and 17.0%—come from a second analysis that estimates results as if participants had stayed on assigned treatment through the full year.

Here's the full picture in one table. This is the part most articles get wrong, so we built it the honest way.

The MariTide Evidence Decoder—Phase 2 results at 52 weeks

Source: Phase 2 trial NCT05669599, published in the New England Journal of Medicine (PubMed record), and Amgen's June 23, 2025 results release. The trial included 592 adults. It tested 140, 280, and 420 mg every four weeks, one 420 mg every-eight-weeks arm, and dose-escalation arms.

Why are there two sets of numbers?

Because the trial answered two different questions, and both are legitimate:

• The “count everyone” analysis—the treatment-policy estimand—includes people based on the group they were assigned to, whether or not they stayed on treatment. Missing results after treatment stopped were handled with conservative statistical assumptions. It answers: what happened under the trial's real conditions? That's the 12.3%–16.2% range for people without diabetes.
• The “if participants stayed on it” estimate—the efficacy estimand—estimates what would have happened if participants had continued their assigned treatment through week 52. It answers: what might the drug do when treatment is continued? That's the 16.3%–19.9% range.

Neither number is a lie. But when a headline quotes only the 19.9% without the asterisk, it's quoting the best-case analysis as if it were the everyday result. We lead with the count-everyone result. You deserve both.

The genuinely exciting part: no plateau

One finding stood out even to skeptics: at week 52, the weight-loss curve had not flattened. That is a real signal of promise. It is not proof that the same pace would continue. The 72-week Phase 3 weight-management trials are designed to give a longer answer.

Trial averages are not your forecast

A 12%–16% average does not show how wide the individual results were. Participants were screened, monitored, and followed inside a clinical trial—conditions your bathroom scale doesn't come with. Use these numbers to judge the drug's early evidence, not to predict your body.

The MariTide pounds calculator—no form needed

Multiply your starting weight by the two percentages for your group:

• No diabetes, count everyone: starting weight × 0.123 to starting weight × 0.162
• No diabetes, stayed-on-treatment estimate: starting weight × 0.163 to starting weight × 0.199
• Type 2 diabetes, count everyone: starting weight × 0.084 to starting weight × 0.123
• Type 2 diabetes, stayed-on-treatment estimate: starting weight × 0.121 to starting weight × 0.170

The same math works in pounds or kilograms.

This is a math illustration, not a prediction. It converts group averages from one Phase 2 trial into pounds. MariTide is investigational, individual results vary, and no clinician can prescribe it as an approved medicine.

How does MariTide work?

MariTide does two things at once inside one long-acting molecule: it switches ON the GLP-1 receptor, a gut-hormone signal tied to appetite and blood sugar, and it BLOCKS the GIP receptor, a second gut-hormone signal. That combination is different from every approved weight-loss drug. Its antibody-peptide design gives it a mean half-life of about 21 days, which supports monthly dosing.

The strange twist: two opposite drugs, same result

Here's a fact that puzzles even scientists. Zepbound (tirzepatide) turns the GIP switch ON. MariTide turns the same switch OFF. Both cause major weight loss in trials. How can activating and blocking the same receptor both work? Researchers are still working that out, and there is no settled human answer yet. What matters for you: MariTide isn't a copycat of Zepbound or Wegovy. It's a genuinely different mechanism, which is why its trials matter on their own terms.

The Iceland clue

MariTide's design didn't come from guesswork. Amgen says its deCODE Genetics team in Iceland analyzed DNA from hundreds of thousands of people and found a genetic signal pointing toward blocking the GIP receptor. Amgen then paired GIP blocking with GLP-1 activation, a pathway already known to affect appetite and blood sugar. That human-genetics clue helped shape the molecule. (Amgen's May 2026 account)

What “antibody-peptide conjugate” means in plain English

Most GLP-1 drugs are peptides—short protein-like chains. MariTide is built differently: one full-size antibody is linked to two matching GLP-1 peptide analogs. The peptides activate GLP-1 receptors. The antibody blocks GIP receptors and helps the whole molecule stay in the body longer. Think of the peptides as two notes and the antibody as a sturdy courier that keeps carrying them for weeks. One molecule, two jobs, slow exit.

That design has a practical consequence you should know: antibody drugs are biologics made in controlled cell-based manufacturing systems. They cannot be copied through ordinary pharmacy compounding under federal law—a fact that matters a lot when we get to the “MariTide for sale” websites below.

Is MariTide really a once-a-month shot?

Monthly is the starting schedule—but it is no longer the whole story. Amgen's August 4, 2026 update says MariTide's long-acting design supports starting monthly and staying on treatment with “as few as 4 or 6 doses per year.” Phase 3 studies are testing every-8-week and quarterly maintenance schedules. Amgen has also reported exploratory second-year Phase 2 maintenance results with lower monthly or quarterly dosing. None of these schedules is approved.

Here's what different schedules mean in shots per year—the comparison that made MariTide famous.

The Injection Ledger: doses per year, by treatment path

Four shots a year versus fifty-two. You can see why people care. Now the honest caveats.

What the quarterly data already shows—and what it does not

In Phase 2 Part 2, Amgen followed a selected group for a second year: they had lost at least 15% by week 52, and the trial record says they were still taking study drug. Amgen says the “large majority” kept the weight off for another 52 weeks on a lower monthly dose or a quarterly dose. “Large majority” is Amgen's wording; the February update did not publish an exact percentage or arm-by-arm weight values. It also reported very little nausea or vomiting and no new safety signal during that second year.

That is useful evidence, but it is selected maintenance evidence—not proof that a new patient can begin with one shot every three months. Amgen's company update did not include arm-by-arm weight numbers for the quarterly group. The Phase 3 extension and switch studies are meant to answer that question more cleanly. (Amgen's February 3, 2026 update)

The switch study—and the quiet message inside it

In 2026 Amgen opened MARITIME-SWITCH, a Phase 3 study enrolling adults who are already taking weekly tirzepatide or weekly semaglutide and moving them to MariTide—and here's the detail almost no one has noticed: the study's listed MariTide schedules are every eight weeks or quarterly, with no monthly comparison arm. Amgen is testing whether people already treated with a weekly drug can maintain treatment with four to six MariTide shots a year.

Read the quiet message in that trial design: the company building MariTide is planning for a world where people start on today's approved medicines and may switch later. Starting treatment now isn't betting against MariTide. It's literally the scenario Amgen is testing.

Starting is not the same as staying on it

One callout worth pinning: a quarterly maintenance schedule does not mean your first shot would be quarterly. The main Phase 3 weight-loss trials start with a low dose and climb over eight weeks. The four-to-six-doses-a-year idea applies to staying on treatment after the drug is working. Any article implying “one shot every three months, day one” is ahead of the evidence.

What are MariTide's side effects?

The most common side effects in Phase 2 were stomach-related—nausea, vomiting, and constipation. Most were mild to moderate and were concentrated around early dosing. Starting low and climbing the dose slowly cut those problems: in the Phase 2 dose-escalation groups, up to 7.8% of participants stopped over stomach side effects. Tolerability is still one of the biggest questions Phase 3 has to answer.

Let's not dance around it. MariTide's stomach side effects were bad enough to become the drug's defining problem in early testing. When participants jumped straight to high doses with no ramp-up, nausea and vomiting ran high—high enough that Amgen rebuilt its Phase 3 dosing plan around a slower start. If a page tells you MariTide is “well tolerated,” full stop, it's skipping the most important chapter of this drug's story.

Here's the honest good news—and it's genuinely good: the side effects didn't vanish, but Amgen found a slower ramp worth testing, and that ramp has data behind it.

What slow dose escalation changed

• In Phase 2's dose-escalation groups, about 11% stopped over any side effect and less than 8% stopped over stomach side effects. For people who had symptoms, nausea generally resolved within a median of about six days and vomiting within one to two days, mostly around the first dose. (Amgen, November 26, 2024)
• A separate Phase 1 study tested gentler ramps starting at 21 or 35 mg. Vomiting rates were still 24.4% and 22.5%, but no participant stopped because of a stomach side effect. (Amgen, June 23, 2025)
• Those results shaped Phase 3: the main MARITIME weight studies start at 21 mg, then move to 35 mg, then 70 mg over eight weeks before reaching a target dose.

If stomach side effects are the thing you fear most, be clear-eyed: an approved medicine has an FDA label and much more real-world use behind it. Waiting for an experimental one is not automatically the safer choice. Our guide to available MariTide alternatives covers those options honestly.

The bone-density question, handled straight

Questions about bone density surfaced after early MariTide data. Amgen's November 2024 statement says its Phase 2 data showed no association between MariTide use and changes in bone mineral density. That is Amgen's reported finding, not the same thing as a final long-term answer. Larger and longer Phase 3 studies still matter. We're telling you this because you'll find the question if you search—and a page that hides the awkward chapters isn't a page you should trust.

Does a monthly shot mean month-long side effects?

This is the smartest fear people raise, so here's the straight answer. Phase 2 data says most nausea and vomiting clustered around early dosing and usually faded within days—not the whole month. But no injected dose can be taken back.

The comparison needs one correction that many pages miss: weekly medicines do not simply “clear in days.” Zepbound's tirzepatide has a half-life of about five to six days. Wegovy's semaglutide has a half-life of about one week and can remain in circulation for roughly five to seven weeks after the last dose. MariTide's mean half-life is about 21 days. The convenience-versus-reversibility trade-off is real, but every long-acting injection can linger. Phase 3 will test whether MariTide's longer exposure creates a different safety problem.

What's still unknown

Phase 2 involved 592 people for one year, with selected responders followed for a second year in an exploratory maintenance phase. Rare side effects, broader long-term effects, the final commercial dose, and the official warning label all wait on Phase 3 and FDA review. We won't guess at them, and neither should anyone else.

Which Phase 3 MariTide trials are running in 2026?

Amgen's August 4 update names nine Phase 3 MARITIME studies. ClinicalTrials.gov separately lists a 279-person Phase 3 study in Japan, so the current public Phase 3 count is ten. Amgen also lists an enrolling Phase 2b liver-fat study. MARITIME-1, MARITIME-2, and the Japan study are no longer taking new participants. Six studies offer public recruiting routes: cardiovascular disease, heart failure, two sleep-apnea studies, switching from weekly tirzepatide or semaglutide, and elevated liver fat. The two extension studies are only for people who completed MARITIME-1 or -2.

This is the current public map of the late-stage program, assembled from Amgen's August 4 update and the study registry.

The MARITIME Trial Tracker—August 11, 2026

Scope note: this tracker covers the ten publicly listed Phase 3 studies plus the recruiting Phase 2b liver-fat study because those are the late-stage studies and public access paths most readers are looking for. MariTide also has smaller Phase 1 and Phase 2 studies that are active but closed to new enrollment. See every MariTide registry record on ClinicalTrials.gov. Amgen also said three more Phase 3 studies in people with type 2 diabetes were planned to start during 2026. Amgen called both extensions enrolling on August 4, but the registry still listed MARITIME-2 Extension as not yet recruiting when we checked on August 11. Trial records change; always open the live registry record before making plans.

The doors that are closed

The two studies most readers would want—the large, straightforward weight-loss trials—filled up. The Japan study is also closed to new participants. Their extension studies only take people who already completed the parent studies. If your plan was “just join the obesity trial,” that window shut before most people knew it was open. That's how these trials tend to go, which is worth remembering if a future door interests you.

The doors still open

The six public recruiting routes each require a specific condition or treatment history alongside obesity or overweight: established atherosclerotic heart disease (MARITIME-CV), heart failure (MARITIME-HF), sleep apnea with or without PAP treatment (OSA-1 and OSA-2), elevated liver fat (the Phase 2b study), or current weekly tirzepatide or semaglutide treatment (MARITIME-SWITCH). The study team—not this page—decides eligibility. Expect screening, possible placebo in some studies, location limits, and real time commitments.

When results land

The most useful date on the public calendar is January 21, 2027, the estimated primary completion date listed for both MARITIME-1 and MARITIME-2. That is the date the primary endpoint period is expected to be complete. It is not a promised public results date. Amgen has not announced when it will release topline data.

Think one of the open studies might fit your situation? Open the linked ClinicalTrials.gov record above, check locations and recruiting status, and contact the listed study team. It is free to check, and the registry is more current than any article—including this one.

When will MariTide be FDA approved and available?

Nobody knows, and no honest page will hand you a confirmed year. Amgen has not announced an FDA filing, approval date, launch date, or price. The clearest public milestone is the January 21, 2027 estimated primary completion date for MARITIME-1 and -2. Primary completion is not the same as results, a filing, or approval.

The five steps between here and a pharmacy shelf

1. Finish the pivotal trials—the main Phase 3 weight studies must complete their planned endpoint periods.
2. Analyze the results—Amgen must lock the data, check safety, and build the full evidence package.
3. File with the FDA—because MariTide is a biologic, this would normally mean a biologics license application with clinical and manufacturing data.
4. FDA review—under the traditional system, FDA's stated goal is action within about 10 months for standard review or six months for priority review. Those are goals, not promises. A newer national-priority voucher pilot can be faster for selected applications. Amgen has announced no MariTide filing, so no public review clock is running.
5. Approval and launch—only after approval can Amgen market it and pharmacies dispense it as an approved medicine. Manufacturing work can begin earlier, but a commercial launch still depends on approval and supply.

Why “MariTide arrives in 2028” is a guess wearing a suit

Some sites confidently print 2028. That year is possible, but it is not an Amgen date. A January 2027 primary-completion estimate is not a January 2027 results promise. Amgen would still need to analyze the studies, decide when to file, complete the application, pass FDA review, and prepare supply. Any one of those steps can move. Amgen has named no year, so neither will we.

How much will MariTide cost?

Unknown—and any current dollar figure is a forecast, not a verified price. There is no approved product, so there's no list price, insurance policy, savings card, or telehealth price to verify. We won't guess based on Wegovy or Zepbound; a monthly antibody-peptide biologic does not have to follow weekly-peptide pricing.

Will insurance cover it?

Also unknown, for the same reason. Coverage decisions come after approval, one insurance plan at a time. Anyone “confirming” future coverage is making it up.

MariTide vs. Zepbound and Wegovy: what's actually different?

MariTide cannot honestly be called better than Zepbound or Wegovy. No completed head-to-head trial compares MariTide with either one, and only Zepbound and Wegovy are FDA approved and available. MariTide's clearest possible edge is fewer injections: 13 shots a year to start and perhaps four to six for maintenance, versus 52 weekly shots. Whether that convenience leads to better real-world results is unproven.

One useful anchor already exists among approved drugs. In the 72-week SURMOUNT-5 head-to-head trial in adults with obesity or overweight without diabetes, Zepbound's tirzepatide averaged 20.2% weight loss versus 13.7% with Wegovy's semaglutide. So the roughly 20% club isn't waiting on MariTide—it already has a member you can get by prescription. (New England Journal of Medicine)

Different trials enroll different people, run for different lengths, use different doses, and handle treatment stops differently. Cross-trial percentage tables are context, never a verdict. If your real question is “which available drug should I get,” that's a different page: compare what you can actually start now. The final choice belongs with a licensed clinician who knows your health history.

Should you wait for MariTide or start a treatment path now?

Waiting makes sense only if MariTide itself is your goal, you're comfortable with an unknown timeline, and your clinician agrees that waiting does not leave a health need untreated. If weight-related health problems are on the table today, the realistic move is discussing approved options now. You do not have to wait to act—and switching later is exactly the scenario Amgen's own SWITCH trial is testing.

Find your row:

Here's the wait math, plainly: there is no reliable countdown. The earliest major Phase 3 milestone on the public record is January 21, 2027, and that is only estimated primary completion. Results, filing, review, approval, and launch come later. Waiting means choosing an unknown timeline for a drug that still has to prove its full benefit-risk profile.

Meanwhile, FDA-approved treatment paths—weekly Zepbound, daily Foundayo or Wegovy tablets, and others—exist now. Through Ro (sponsored affiliate link), the Ro Body membership is $39 for the first month, then $149 month to month or as low as $74 per month with an annual plan paid upfront. Medication costs extra and depend on the drug, dose, insurance, and current cash-pay offer.

Not sure which path fits your state, budget, and preferences? Get your personalized GLP-1 action plan → Free, 60 seconds, no signup—built from source-verified pricing.

Or start with the full landscape: every real MariTide alternative available in 2026, compared and priced.

What MariTide claims should make you skeptical?

Be skeptical of anyone selling “MariTide” for human use, anyone quoting 19.9% as the everyday result, anyone presenting an approval year as official, and anyone declaring it better or safer than approved drugs. Each claim runs ahead of—or flatly against—the evidence.

We fact-checked the claims circulating right now:

FDA warns that unapproved drugs sold online do not go through its approval review for safety, effectiveness, and quality. With an online “MariTide” vial, you do not have an FDA-approved label, verified supply chain, or proof that the contents match Amgen's clinical material. If you've run into a “MariTide for sale” listing and want the full checklist for spotting bad sellers, we keep it updated in our alternatives guide.

What we actually verified for this page

We checked Amgen's August 4, 2026 pipeline update, the published Phase 2 results, Amgen's second-year maintenance report, current ClinicalTrials.gov records, FDA compounding rules, current FDA labels, and live Ro pricing. We marked price, timing, coverage, and superiority claims as unknown rather than guessing. “Sponsor-stated” below means the manufacturer or provider published the claim. “Registry, FDA, or peer-reviewed” means we checked it outside the seller's own page. Here's the receipt.

Who made this page: The RX Index Editorial Team. How: primary-source review of Amgen releases, the peer-reviewed Phase 2 report, FDA records, current prescribing information, registry records, and provider pricing on August 11, 2026, with every consequential claim classified before publishing. Why: MariTide is one of the most-hyped drugs in this field, and much of what appears for it is outdated, overclaimed, or trying to sell you something that is not an approved medicine. We'd want a friend to get the straight version. This is it.

MariTide FAQ

People ask us three questions more than any others: “Is it real?” (yes), “Can I get it?” (not as an approved medicine), and “Should I wait for it?” (usually not without a health reason and a clinician's plan). Here's everything else, answered straight.

Is MariTide a GLP-1?

Partly. It activates the GLP-1 receptor like Wegovy does, but it also blocks the GIP receptor. The more exact description is a GLP-1 receptor agonist plus a GIP receptor antagonist.

What is maridebart cafraglutide? What is AMG 133?

Both names refer to MariTide. Maridebart cafraglutide is the scientific name. AMG 133 was Amgen's earlier development code.

Is MariTide FDA approved?

No. It is investigational and in Phase 3 trials. There is no FDA-approved MariTide product.

Can a doctor prescribe MariTide?

No. There is no approved product or lawful pharmacy-compounded biologic to prescribe. The only publicly listed access route is a qualifying clinical trial, and enrollment does not guarantee active drug in a blinded or placebo-controlled study.

Can I buy MariTide online?

Not as an approved medicine. A product labeled “MariTide” or “AMG 133” online is not an FDA-approved MariTide treatment and cannot be verified as Amgen's trial supply. Treat any human-use sales claim as a serious red flag.

Is there a compounded version of MariTide?

No lawful pharmacy-compounded version exists. FDA says biological products are not eligible for the 503A or 503B compounding exemptions.

Does MariTide come as a pill?

No. The current clinical program studies MariTide as an injection under the skin.

How often is MariTide taken?

For people starting MariTide in the main weight-loss program, dosing starts monthly. Switch and maintenance studies test every-8-week and quarterly schedules. Amgen also reported exploratory second-year maintenance in selected Phase 2 responders using lower monthly or quarterly doses. None is an approved schedule.

Did people really lose 20% on MariTide?

The top estimate was 19.9% at 52 weeks under the analysis that assumed participants stayed on treatment. Under the count-everyone analysis, adults without diabetes lost an average of 12.3%–16.2%.

Does MariTide work for people with type 2 diabetes?

In Phase 2, participants with type 2 diabetes lost an average of 8.4%–12.3% under the count-everyone analysis. Their average HbA1c fell by 1.2 to 1.6 percentage points under that analysis; the earlier 2.2-point headline came from the stay-on-treatment estimate.

Is MariTide better than Zepbound or Wegovy?

Not established. No completed head-to-head trial compares them, and only Zepbound and Wegovy are approved. MariTide's clearest possible advantage is fewer injections.

MariTide vs. retatrutide—what's the difference?

They come from different companies and work differently. Retatrutide is Lilly's investigational once-weekly drug that activates GIP, GLP-1, and glucagon receptors. MariTide is Amgen's investigational monthly-start drug that activates GLP-1 and blocks GIP. Both remain investigational, and no trial compares them directly.

When will MariTide be available?

No date exists. MARITIME-1 and -2 list January 21, 2027 as an estimated primary completion date. That is not a results, filing, approval, or launch date. Any specific launch year is a forecast.

How much will MariTide cost?

Unknown. There is no approved product to price, so every current dollar figure is a guess.

How do I join a MariTide clinical trial?

Use the live study links in the trial tracker above, check the locations and criteria, and contact the listed study team. The team decides eligibility—never an article.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Get my personalized GLP-1 action plan →

Compare treatment paths based on your state, insurance, preferred format, and budget. MariTide isn't included as an available option—because it isn't one yet. The moment that changes, this page and the quiz will too.

Sources

• Amgen—Q2 2026 financial results and pipeline update, August 4, 2026
• Jastreboff A.M., et al.—Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity, New England Journal of Medicine, 2025
• Amgen—Phase 2 and Phase 1 PK-LDI full results, June 23, 2025
• Amgen—52-week Phase 2 topline results, November 26, 2024
• Amgen—Phase 2 Part 2 maintenance update, February 3, 2026
• Amgen—The Story of Maridebart Cafraglutide, May 11, 2026
• Nature Metabolism—A GIPR antagonist conjugated to GLP-1 analogues, 2024
• ClinicalTrials.gov—MARITIME-1
• ClinicalTrials.gov—MARITIME-2
• ClinicalTrials.gov—Japan Phase 3 study
• ClinicalTrials.gov—MARITIME-CV
• ClinicalTrials.gov—MARITIME-HF
• ClinicalTrials.gov—MARITIME-OSA-1
• ClinicalTrials.gov—MARITIME-OSA-2
• ClinicalTrials.gov—MARITIME-SWITCH
• ClinicalTrials.gov—MARITIME-1 Extension
• ClinicalTrials.gov—MARITIME-2 Extension
• ClinicalTrials.gov—Phase 2b liver-fat study
• FDA—Compounding and the FDA: Questions and Answers
• FDA—FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• FDA—Priority Review
• FDA—Foundayo approval, April 1, 2026
• FDA—Wegovy prescribing information, revised February 2026
• FDA—Zepbound prescribing information, 2026
• SURMOUNT-5—Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, New England Journal of Medicine, 2025
• Lilly—What to know about retatrutide, updated July 2026
• Ro—Weight Loss Program Pricing, verified August 11, 2026

Trial status, program details, regulatory status, and provider pricing can change. We re-verify this page quarterly and after every major Amgen update. We change the “Last verified” date only when we have actually rechecked it.